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Abstract
The aquaporins (AQP) are water channel proteins playing a major role in transcellular and transepithelial water movement.
Recently, the role of AQPs in human carcinogenesis has become an area of great interest. Here, by immunohistochemistry
(IHC), we have found an expression of AQP5 protein in 35.3% (IHC-score: $1, 144/408) of the resected NSCLC tissue
samples. Cases with AQP5-positive status (IHC-score: $2) displayed a higher rate of tumor recurrence than negative ones in
NSCLC (54.7% vs. 35.1%, p=0.005) and worse disease-free survival (p=0.033; OR=1.52; 95%CI:1.0422.23). Further in vitro
invasion assay using BEAS-2B and NIH3T3 cells stably transfected with overexpression constructs for full length wild-type
AQP5 (AQP5) and its two mutants, N185D which blocks membrane trafficking and S156A which blocks phosphorylation on
Ser156, showed that AQP5 induced cell invasions while both mutants did not. In BEAS-2B cells, the expression of AQP5
caused a spindle-like and fibroblastic morphologic change and losses of cell-cell contacts and cell polarity. Only cells with
AQP5, not either of two mutants, exhibited a loss of epithelial cell markers and a gain of mesenchymal cell markers. In a
human SH3-domains protein array, cellular extracts from BEAS-2B with AQP5 showed a robust binding activity to SH3-
domains of the c-Src, Lyn, and Grap2 C-terminal. Furthermore, in immunoprecipitation assay, activated c-Src,
phosphorylated on Tyr416, showed a stronger binding activity to cellular extracts from BEAS-2B with AQP5 compared
with N185D or S156A mutant. Fluorescence in situ hybridization (FISH) analysis failed to show evidence of genomic
amplification, suggesting AQP5 expression as a secondary event. Based on these clinical and molecular observations, we
conclude that AQP5, through its phosphorylation on Ser156 and subsequent interaction with c-Src, plays an important role
in NSCLC invasion and, therefore, may provide a unique opportunity for developing a novel therapeutic target as well as a
prognostic marker in NSCLC.
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Introduction
The aquaporins (AQP) represent a family of transmembrane
water channel proteins widely distributed in various tissues
throughout the body and play a major role in transcellular and
transepithelial water movement [1,2]. So far, at least ten distinct
AQPs have been characterized in humans and there has been an
increasing understanding of their roles in human pathophysiology
[2]. However, only recently has data emerged on the role of
human AQPs (hAQPs) as one of the key elements directly involved
in human carcinogenesis [3]. Expression of hAQP1 is frequently
related with colon cancer, pancreatic cancer, brain tumor, renal
cell carcinoma, and microvessels of (MM), paralleling angiogenesis
[4–8]. Likewise, expression of AQP5 was increased in pancreatic
cancer and ovarian cancer [7,9]. Moreover, we have previously
reported the induction of AQP5 expression in its message during
the early colon cancer development [5].
At the functional level, AQP1 is shown to be one of the
delayed early response genes and also involved in cell migration,
and angiogenesis [10,11], and expression of AQP1, AQP3 and
AQP5 were induced during lymphocyte activation [12].
Previously, we have provided evidence for novel oncogenic
properties of AQP1 and its expression in resected tissue samples
from non small cell lung cancer. Further evidence of the role of
AQP5 in human carcinogenesis was also provided by our group
[13,14]. Ectopic expression of AQP5 in NIH3T3 cells induced
many phenotypic changes characteristic of transformation both
in vitro and in vivo by promoting signaling pathways activated
through Ras, which is induced by phosphorylation of the PKA
consensus site of AQP5.
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AQP5 was chosen based on a number of studies: First, our
preliminary study showed that, among AQP1, 3, and 5, AQP5
showed the most robust oncogenic potential in NIH3T3 cell line.
Second, although both AQP1 and AQP5 showed oncogenic
property with NIH3T3 cell line, AQP5 expression induced ERK
activation [13], while AQP1 expression did not [15]. Third, the
expression of AQP5, not AQP1, or AQP3, was found to be
associated with Ras/ERK/Rb pathway activation in colon cancer
cell lines and was linked with liver metastasis in colon cancer
patients [16]. We have previously demonstrated the expression of
AQP1 in human primary lung cancer tissues; 18 out of 44 samples
of non small cell lung cancer patients showed positive AQP1
protein expression. However, it has been shown that AQP5
showed more robust oncogenic potential than AQP1 as well as
AQP3 in soft agar assay, focus formation assay, and cell
proliferation (MTT) assay [13–15], leading us to choose AQP5
for its role in lung carcinogenesis not only for clinical validation
study but also for studies in its underlying molecular mechanisms.
Here, we present both molecular and clinical evidence that
AQP5 may play a role in the progression of non small cell lung
cancer (NSCLC). First, based on immunohistochemical analysis of
hAQP5 with 408 NSCLC tissues, we have investigated whether
expression profile of AQP5 in human lung cancer correlates with
disease progression and survival. Then, we have performed
invasion assay and epithelial-mesenchymal transition marker study
in human bronchial epithelial cells overexpressing AQP5 versus its
mutants in addition to mock control, followed by further
molecular interaction studies to elucidate AQP5 mediated
pathway. Moreover, FISH analysis was done to identify molecular
mechanisms underlying hAQP5 expression.
Methods
Cell culture
All cell lines were obtained from the American Type Tissue
Collection (Rockville, MD). The murine fibroblast cell line
NIH3T3 was cultured in DMEM in the presence of 10% FBS.
The normal lung cell line BEAS-2B was grown in LHC-9 medium
in the presence of 0.5 ng/ml recombinant epidermal growth factor
(EGF), 500 ng/ml hydrocortisone, 0.005 mg/ml insulin,
0.035 mg/ml bovine pituitary extract, 500 nM ethanolamine,
500 nM phosphoethanolamine, 0.01 mg/ml transferrin, 6.5 ng/
ml 3,39,5-triiodothyronine, 500 ng/ml epinephrine, 0.1 ng/ml
retinoic acid (Clonetics Corporation, Walkersville, MD). All cells
were cultured in 5% CO2 balanced air at 37uC.
Plasmid constructs and production of stable cell lines
Human cDNA from HEK 293 was amplified by polymerase-
chain reaction (PCR) using primers for wild-type AQP5 (AQP5)
and then inserted into EcoR I and XhoI site of pcDNA 3.1(+).
Clones were confirmed by restriction analysis and by DNA
sequencing of both strands. Serine 156 or Asparagine 185 was
replaced with alanine or aspartic acid, respectively, by PCR-based
site-directed mutagenesis to produce the S156A or N185D AQP5
mutant based on the AQP5 pcDNA3.1 construct as previously
described [13]. AQP5 WT and two mutants were inserted into the
EcoR I and BamH I sites of p3XFLAG-CMV-14 (SIGMA) and
verified by DNA sequencing of both strands of the mutants.
Expression constructs were transfected into NIH3T3 and BEAS2B
cells with FuGENE 6 according to manufacturer’s recommenda-
tions. All transfectants were selected with 800 mg/mL G418 for 3
weeks and selected clones were screened with Western blot using
AQP5 antibody and/or RT-PCR. When confluent, cells were
subcultured by trypsinization (0.05% trypsin, 0.53 mM EDTA in
Hanks’ balanced salt solution). The pictures that show the
morphologies of various stable cells expressing different constructs
were taken through phase contrast microscopy (ECLIPSE TE300,
Nikon Co., Tokyo, Japan).
Invasion assay
Matrigel invasion assay was performed with NIH3T3 and
BEAS2B cells. BioCoat Matrigel (BD Biosciences, Bedford, MA)
that reconstitutes the basal membrane was purchased to assess cell
invasion. 24-well tissue culture plate inserts coated with Matrigel
were re-hydrated for 2 hours in 37uC media. Media (0.6 ml)
containing 5% fetal bovine serum was added to each plate well as
a chemoattractant, and 0.2 ml (2610
4 cells) of cell suspension was
added to each insert. After incubation for 24 hours, non-invading
cells were removed from the upper side of the membrane by
scrubbing. To minimize the effect of cell proliferation on the
invasion assay, we have confirmed that, in the first 24 hours,
BEAS-2B cells undergo minimal cell division and do not show any
noticeable difference in cell proliferation between cells expressing
AQP5 and cells expressing mock vector (Fig. S1). Invasion of cells
to the underside of the Matrigel-coated membrane was detected
by staining the cells with Mayer’s hematoxylin solution and
visualizing the cells under a microscope. After staining, cells were
counted under a microscope in four randomly selected fields
(magnification 6100) and results were expressed in the form of a
bar graph. Assays were performed with triplicate wells for each
condition.
Immunoblotting and immunoprecipitation
Lysates from cultured cells and tissues were prepared in ice-cold
NP-40 lysis buffer (10 mM Tris-HCl (pH 7.4), 137 mM NaCl,
10% glycerol and 0.1% Nonidet P-40) containing an inhibitor
cocktail of 10 mM b-glycerol phosphate, 1 mM phenylmethylsul-
fonyl fluoride, 10 mM NaF, 10 mM Na orthovanadate, 4.5 U/ml
aprotinin (Sigma), and 1 mg/ml leupeptin (Sigma). Crude protein
lysates (30 mg) were separated by 12% SDS-PAGE (BIORAD),
transferred to nitrocellulose membranes (BIORAD), and blocked
for 1 hour with 5% nonfat dry milk in Tris-buffered saline with
0.05% Tween 20. The following commercial antibodies were used
for Western blot analysis: anti-AQP5 (1:200, Alpha Diagnostic),
anti-a-catenin antibody (1:1000, Cell Signaling) anti-c-catenin
antibody (1:1000, Cell Signaling), anti-fibronectin antibody
(1:1000, Cell Signaling), anti-vimentin antibody (1:1000, Cell
Signaling), anti-E-cadherin antibody (1:1000, Cell Signaling), anti-
c-Src antibody (1:1000, Cell Signaling), anti-phospho Src antibody
(1:1000, Cell Signaling), anti-Lyn antibody (1:1000, Cell Signal-
ing), anti-grap2 antibody (1:1000, Cell Signaling), and anti-b actin
antibody (1:5000; Sigma). Phospho-Src antibody was first used;
blots then were stripped and re-blotted with anti-src and beta-actin
antibodies. Appropriate anti-rabbit and anti-mouse horseradish
peroxidase-conjugated secondary antibodies (1:3000; Amersham)
were used. Immunoreactive bands were detected by enhanced
chemiluminescence (Pierce).
SH3 domain binding
TranSignal SH3 domain array III spotted with peptides
representing 34 different human SH3 domains including Grb2
and Src, were purchased from Panomics and tested for their
binding to AQP5 segments and AQP5 WT maintaining natural
topology according to the manufacturer’s instruction. The SH3
domain-containing proteins on the array were spotted in duplicate.
Briefly, membrane filters incubated with 30 mg/ml protein for
overnight. After washing, protein binding was visualized by
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body. This assay was performed at least twice with each protein.
Protein identification and interaction
For pull-down assays, GST fusion proteins (SH3 domain-
containing proteins) and GST were purchased from Panomics.
Cells were lysed in NP-40 lysis buffer, and lysates were then
incubated with either GST or GST fusion protein at 4uC for
2 hours, followed by the addition of 20 ml glutathione-Sepharose
4B beads. After 30 minutes of mixing, the beads were washed four
times. Proteins were eluted in Laemmli sample buffer and were
analyzed by SDS-PAGE followed by immunoblot with indicated
antibodies.
Cancer tissue microarray
Tissue microarrays (TMAs) were constructed using formalin-
fixed, paraffin-embedded tissues of 419 NSCLC obtained from the
Department of Pathology of Asan Medical Center under the
approval of the Internal Review Board (IRB number: 2006-0019).
The lung samples were obtained from 1996 to 1999. The original
H&E stained slides were reviewed by study pathologists and
representative areas of each tumor were arrayed to the triplicated
blocks to minimize the tissue loss and overcome the heterogeneity
of the tumors.
Immunohistochemistry
The immunostaining procedures were performed using the
Benchmark automatic immunostaining device (Ventana Medical
System, Tucson, AZ, USA) with affinity-purified goat antibody
raised against the 19-amino acid sequence (aa 251–269) of the
COOH-terminus of human AQP5 (Alpha Diagnostic, San
Antonio, Texas) at a 1:50 dilution. Tissue array sections (4 mm-
thick) were deparaffinized in xylene, rehydrated in graded
alcohols, and treated with 3% hydrogen peroxide in methanol at
room temperature for blocking of endogenous peroxidase activity.
The AQP5 antibody was visualized using the avidin-biotin-
peroxidase technique (DAKO LSAB kit; DAKO Cytomation,
Carpinteria, CA) and followed by chromogen detection with
diaminobenzidine (DAB). Negative controls were performed by
omitting the primary antibody incubation step.
Scoring of immunohistochemistry
Immunostaining on the TMAs was graded semi-quantitatively
considering both staining intensity and percentage of positive
tumor cells by two study pathologists (S.J.J. and M.J.K.) blinded to
the clinicopathologic variables. The staining intensity was scored
on a scale of four grades: 0, no staining of cancer cells; 1, weak
staining; 2 moderate staining; 3, strong staining. The percentage of
stained tumor cells was graded on a scale of 2 grades: 0, ,10%
and 1, .10%. AQP5 expression in the cancer tissue was defined as
positive when the product of intensity score by percentage score is
1 or more. Both histological type and grade were confirmed on
hematoxylin and eosin (H&E) stained TMA slides.
Fluorescence in situ hybridization analysis
Sixty-nine NSCLCs which had an expression of AQP5
(score=2 or 3) were reassembled in two TMA blocks for FISH
analysis, each. Sections (5 mm thick) of the TMA slides were
deparaffinized and pretreated for FISH. The probe for AQP5
detection was derived from Homo sapiens 12 BAC RP11-469H8
containing the whole AQP5 gene (GenBank Accession no.
AC025154), and labeled with rhodamin (Macrogen, Seoul,
Korea). Two genomic DNA clones with 91 kb and 68 kb sizes
franking 12p13.31 region labeled with FITC were used as control
probes (Macrogen, Seoul, Korea). FISH was performed using
Vysis reagents according to the manufacturer’s protocols (Vysis,
IL, USA). Slides were counterstained with 4, 6-diamidino 2-
phenylindole for microscopy. The signal was counted under
61000 magnification.
Statistical Analysis
Statistical analyses were performed using the chi-square test
with SPSS software (SPSS 12.0K Inc., Chicago, Illinois, USA).
The patients’ mean age and tumor size were evaluated by t-test.
Survival curves were produced using the Cox proportional hazards
model to test the risk of cancer death. Prognostic factors were
examined by both univariate and multivariate analyses. In
multivariate analysis, age, sex, histological grade, and tumor stage
were accounted for. We did not control for treatment methods
since a majority of the patients underwent surgery and the TNM
stage based on which treatment modalities are decided, demon-
strated no association with AQP5 expression. All p-values were
two-sided, and differences at p,0.05 were considered statistically
significant.
Results
AQP5 overexpression is associated with worse prognosis
in NSCLC
A significant expression of AQP5 protein was observed in
16.9% (69/408) of NSCLC TMA samples (immunostaining score
of 2+; defined as positive) (Table 1, Fig 1A). As shown in the
figure 1A, only cancer cells, not tumor-infiltrating lymphocytes,
showed AQP5 expression. Including cases with weak expression
(immnunostaining score of 1+), it was as high as 35.3% (144/408,
Table 1). Interestingly, AQP5 overexpression was observed
predominantly in lung adenocarcinomas (p,0.001, Table 2).
However, no other statistically significant correlation was found in
NSCLCs between AQP5 expression and demographic and
Table 1. The immunostaining scores of AQP5 and the histological subtype of NSCLC.
AQP5 immunostaining score 0 1 2 3 Total
Adenocarcinoma 101 (54%) 34 (18%) 25 (13%) 28 (15%) 188 (46%)
Squamous cell carcinoma 148 (74%) 39 (20%) 6 (3%) 7 (3.5%) 200 (49%)
Large cell carcinoma 13 (86%) 0 (0%) 1 (7%) 1 (7%) 15 (4%)
Others^ 2(40%) 2 (40%) 1(20%) 0 (0%) 5 (1%)
Total 264 (65%) 75 (18%) 33 (8%) 36 (9%) 408 (100%)
^Other subtypes include three adenosquamous, one mixed squamous and neuroendocrine carcinoma and one sarcomatoid carcinoma.
doi:10.1371/journal.pone.0002162.t001
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tumor stage (Table 2). Due to the insufficient sample size of
metastatic cases (n=4), no further statistical correlation study on
metastasis was performed.
To our surprise, cases with AQP5-positive status displayed a
higher rate of tumor recurrence than negative ones in NSCLC
(54.7% vs. 35.1%, p=0.005). Although AQP5 overexpression was
not statistically significantly related with overall survival, remark-
ably, those with NSCLC showed a worse disease-free survival rate
(log rank test, p=0.011) (Fig. 1B). Even after adjusting for
histological grade and tumor stage, AQP5 overexpression in
NSCLC was still significantly associated with earlier disease
progression (p=0.033; OR=1.52; 95% CI: 1.04–2.23). There-
fore, AQP5 status seems to be an independent molecular marker
associated with worse clinical outcomes.
Human AQP5 promotes cell invasion
From our clinical findings, we have hypothesized that AQP5
may induce cell invasion, a necessary step for tumor metastasis. In
order to investigate whether AQP5 overexpression promotes cell
invasion in human bronchial epithelial cells and, at the same time,
to determine what components of AQP5 protein plays a role in the
process, we first performed Matrigel invasion assay in BEAS-2B
cell lines stably expressing AQP5 and its two mutants, N185D
which blocks membrane trafficking and S156A which blocks
phosphorylation on S156 site of AQP5 molecule [13,14,17].
Interestingly, cells with AQP5 demonstrated the highest degree of
cell invasion among four groups (Fig. 2A, 2C). Although higher
than the mock, the degree of cell invasion in cells with N185D and
S156A mutants was clearly less than that of cells with AQP5
(Fig. 2A, 2C). These findings suggest that both membranous
expression of AQP5 and its phosphorylation on S156, the PKA
consensus site, are important for AQP5 induced cell invasion in
BEAS-2B cells. To exclude the possibility that this phenomenon is
not unique to human bronchial epithelial cells, we performed the
same assay using mouse fibroblast NIH3T3 cell lines, which were
transfected with same expression constructs [13] and have
observed similar findings (Fig. 2B, 2D).
AQP5 expression leads to fibroblast-like morphologic
change in bronchial epithelial cells
We, then, decided to assess any morphologic changes
accompanied by AQP5 overexpression. The morphologies of the
BEAS-2B human bronchial epithelial cells carrying either the
mock vector FLAG or FLAG/AQP5 were examined by phase
contrast microscopy. As expected, mock transfected BEAS-2B cells
showed highly organized cell-to-cell adhesion and maintained cell
polarity, which is the typical morphology of normal epithelial cells
(Fig. 3). However, the expression of AQP5 caused a marked
spindle-like and fibroblastic change in cell morphology and a loss
of cell-to-cell contact and cell polarity (Fig. 3). These morphologic
alterations may imply that AQP5 plays a role in epithelial-
mesenchymal transition (EMT).
AQP5 expression is associated with molecular markers of
epithelial-mesenchymal transition
In order to confirm whether AQP5 really induces EMT in
human bronchial epithelial cells, we performed western blot
analysis to check protein markers for EMT. Of note, among
BEAS-2B cells stably expressing AQP5 (clone #1 and #2),
N185D, S156A mutants and mock vector, only cells that express
AQP5 exhibited a loss of epithelial cell markers, such as E-
cadherin, a catenin and c catenin, and a gain of mesenchymal cell
markers including fibronectin and vimentin (Fig. 4). Both changes
in the morphology and the molecular profile of AQP5 overex-
pressing cells provide firm evidence that AQP5 stimulates
bronchial epithelial cells to undergo EMT.
AQP5 interacts with the c-Src, a potent EMT trigger
Then, we investigated the possible molecular mechanism
behind the EMT promoting property of AQP5. Human AQP5
carries a diproline peptide sequence (RTSPVGSP) in the loop D
[18,19] which bears a sequence similarity to the SH3 binding
consensus site. Thus, it is possible that this segment of AQP5 may
bind with the SH3 domain of an adaptor molecule [18].
Therefore, we performed a human SH3 domains protein array
to examine the potential of several SH3 domain containing
proteins to bind to human AQP5. Notably, the purified AQP5
from stable BEAS-2B cells showed binding activity to the SH3
domain of c-Src, Lyn, and Grap2 C-terminal (Fig 5A). The AQP5
segment containing a phosphorylated Loop D (88 aa through
182 aa) was also able to bind the SH3 domain of c-Src, Lyn, and
Grap2 C-terminal (Fig. 5A). The AQP5 segment containing an
unphosphorylated Loop D, however, was unable to bind to any
SH3 domains from three proteins (Fig. 5A). The phosphorylation
status of each protein was further confirmed.
In addition, we performed a GST pull-down assay to verify a
direct interaction between AQP5 and the Src family molecules. In
this assay, we used three different GST fusion proteins: a c-Src
SH3 domain, a Lyn SH3 domain, and a C-terminal Grap2 SH3
domain protein, which were identified to interact with AQP5 in
SH3 domain protein arrays. Consistent with the result from SH3
domain protein arrays, AQP5 stably expressed in BEAS-2B
human bronchial epithelial cells exhibited a strong interaction with
Figure 1. Clinical importance of AQP5 in non small cell lung
cancer. (A) Immunohistochemistry of AQP5. Photomicrographs of
AQP5 immunostaining in arrayed non small cell lung cancer (NSCLC)
tissues. Examples of weak (+1), moderate (+2), and strong (+3)
immunoreactivity in NSCLCs (a to c, respectively) Original magnification
6200. (B) Kaplan Meier Curve in NSCLC patients. AQP5-positive
cases displayed a less favorable disease-free survival rate (log rank
p=0.011) than AQP5-negative cases.
doi:10.1371/journal.pone.0002162.g001
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(Fig. 5B).
Lastly, to confirm our finding in vivo, we performed an
immunoprecipitation assay in human bronchial epithelial cell
line, BEAS-2B. This time, we focused on c-Src, a molecule well
known for its EMT promoting activity [20]. As expected, AQP5
co-immunoprecipitated with c-Src in cells stably expressing AQP5
(Fig. 5C). Intriguingly, c-Src co-immunprecipitated with AQP5
turned out to be an activated form of c-Src, which is
phosphorylated at Tyr416 (Fig. 5C). We also note that the cells
expressing AQP5 have more activated c-Src than the cells carrying
N185D or S156A mutant (Fig. 5C), which suggests that the
interaction with AQP5 may be an important step in activating c-
Src.
AQP5 overexpression may not be associated with
genomic amplification
To elucidate the molecular mechanisms underlying AQP5
overexpression, we have investigated the presence of genomic
amplification through FISH analysis. Out of 69 interpretable cases
of NSCLC TMAs, not a single clear pattern of genomic
amplification was detected (Fig. S2), which suggests that the
ectopic expression of AQP5 could be a secondary molecular event.
Discussion
We have previously demonstrated that overexpression of AQP5
in mouse fibroblasts, NIH3T3 cells, induces cell proliferation
secondary to the activation of Ras, which is mediated by
phosphorylation of AQP5 in its PKA consensus site (S156) and
this study clearly provided an association between AQP5 and the
Ras signal transduction pathway [13,14]. Additionally, we have
recently reported a study which describes an induced expression of
AQP5 protein during colorectal carcinogenesis and molecular
pathways how AQP5 protein expression can influence colon
cancer development by its interaction with the Ras/ERK/Rb
signaling pathway [16].
In contrast to these previous reports, here, we have pursued the
role of AQP5 on the progression of NSCLC. This is partly based
on our prior report, which not only showed the oncogenic
property of AQP1 in NIH3T3 cells, but also described the
expression profile of AQP1 in NSCLC [15]. This report, although
provided certain insight regarding the role of AQPs in NSCLC,
did not demonstrate either its clinical implication or related
molecular pathways. In our preliminary study for AQP5 in
NSCLC, we noticed a series of AQP5 expression in several
NSCLC cell lines including H1975, H1838, H1650, H1437, and
H838. In addition, similar to our observations with NIH3T3
mouse fibroblast cells [13,14], we have recently identified that
AQP5 overexpression in BEAS-2B cells induces activation of the
ERK pathway leading to stimulation of cell proliferation (Kang et
al., manuscript in preparation); human bronchial epithelial cells
stably transfected with AQP5 demonstrated significantly higher
proliferation rate than cells stably transfected with mock (Fig. S1).
Based on these preliminary findings and prior observations we had
with AQP1 in NSCLC and AQP5 in colorectal cancer study, we
have examined the expression profile of AQP5 in a large panel of
clinical samples.
While expression of AQP5 in its message level is reported in
certain parts of normal human bronchial and alveolar tissues [21],
so far, AQP5 expression profiles in NSCLC tissue samples, in its
protein level, have not been reported. In order to find clinical
implications of AQP5 overexpression in NSCLC, we have
gathered resected human NSCLC tissues with an average of five
year follow-up, on which we performed immunochemistry to
examine the protein expression level of AQP5. While we found
AQP5 expression in cancer cells, we did not see any evidence of
AQP5 immunoreactivity among tumor-infiltrating lymphocytes,
which is contrary to our previous findings showing an induced
expression of AQP5 messages during lymphocytes activation [12].
Although this discrepancy can be a result of multiple reasons, it is
possible that AQP5 expression during lymphocyte activation can
Table 2. Association between AQP5 overexpression and the
demographics of patients and tumor characteristics.
Clinical findings
Lung cancer^ (AQP(+)/n
=69/408) p-value*
Mean Age (range, yrs) 63.3 (29–86) 0.877
Gender
Woman 34/87 (39.1%) 0.747
Man 93/321 (29.0%)
Histological subtype
Adenocarcinoma 53/188 (28.2%) ,0.001
Squamous Cell Carcinoma 13/200 (6.5%)
Large Cell Carcinoma 2/15 (6.7%)
Others
{ 1/5 (20.0%)
Grade
1
WD (HG 1) 20/110 (18.2%) 0.571
MD (HG 2) 36/201 (17.9%)
PD (HG 3) 13/97 (13.4%)
Mean tumor size (cm) 4.2 0.281
T stage
T1 16/74 (21.6%) 0.221
T2 41/276 (14.9%)
T3 6/35 (17.1%)
T4 6/20 (30.0%)
Unknown 0/3 (0%)
N stage
N0 34/205 (16.6%) 0.196
N1 10/85 (11.8%)
N2 25/117 (21.4%)
N3 not available
Unknown 0/1
TNM stage
I 31/187 (16.6%) 0.353
II 10/85 (11.8%)
III 27/129 (20.9%)
IV 1/4 (25.0%)
Unknown 0/3 (0%)
^In this table, AQP5(+) group is defined as cases with moderate and strong
expression (score 2, and 3). If all of three groups (groups with expression score
of 1, 2, and 3) including the group with weak expression (score 1) are counted,
percentage of expression will be significantly high (45.5%, 185/408).
*Pearson X
2 test was used to derive p values, except for age and tumor size
where student t-test was performed.
{Other subtypes include three adenosquamous, one mixed squamous and
neuroendocrine carcinoma and one sarcomatoid carcinoma.
1Lung cancers are graded by the modified Broder’s grading system (HG,
histological grade; WD, well differentiated; MD, moderately differentiated; PD,
poorly differentiated).
doi:10.1371/journal.pone.0002162.t002
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they may downregulate AQP5 expression.
We have identified three interesting expression profiles of AQP5
protein in NSCLC with clinical correlation. First, an expression of
AQP5 protein is noticed in 35.3% (144/408, Table 1.) of the
resected NSCLC tissue samples. Second, NSCLC cases with
AQP5-positive status displayed a higher rate of tumor recurrence
than negative ones (54.7% vs. 35.1%, p=0.005). Third, AQP5
overexpression in NSCLC was significantly associated with earlier
disease progression (p=0.033; OR=1.52; 95% CI 1.0422.23)
and worse disease-free survival. We believe that this is the first
clinical evidence indicating a strong correlation between AQP5
expression and the outcome of cancer patients who underwent
surgery, and further suggest that hAQP5 is a potential indepen-
dent prognostic marker. Moreover, the fact that this study is based
on a substantial size of patient samples (more than four hundred
cases) with an average of 5 year follow-up corroborates our
findings.
The prognostic marker for lung cancer is crucial as there are still
on-going controversies regarding the post-operative management
and follow-up plans for NSLCLC. Although the needs and the
effects of post-operative chemotherapy are relatively well estab-
lished, there seem to be few candidate prognostic biomarkers from
which the decisions for chemotherapy can be made [22,23]. Part
of this problem stems from the fact that most of the studies were
based on the sample size of less than 200 with an average follow-
up year of less than 5 years [23]. Only a few molecular marker
studies published used a sample size of above 400 [24,25]. Looking
at a 50% increase in terms of recurrence risk in AQP5 positive
group vs. negative group among more than 400 samples with up to
7 year follow-up, study of AQP5 expression in addition to other
prognostic markers in surgical samples may provide a dependable
guidance for making a better informed decision for postoperative
management in NSCLC patients.
Based on our observations with clinical samples from NSCLC
and also from our previous observation in colon cancer [16],
where AQP5 expression was detected in patients with liver
metastasis, we hypothesized that AQP5 is associated with cell
invasion. For our invasion assay, we have decided to use BEAS-2B
stable cell lines stably transfected with AQP5 overexpression
construct and those of two mutants. BEAS-2B is a SV-40
transformed immortalized cell lines originated from normal lung
Figure 2. Invasion assay with stable cells expressing AQP5 and mutants. Matrigel invasion assay was performed with each of BEAS-2B cells
(A, C) and NIH3T3 cells (B, D) which express AQP5 or each of two mutants. AQP5 induced cell migration and invasion in BEAS-2B, immortalized
human bronchial epithelial cells as well as NIH3T3 cells. In contrast, both of the N185D mutant (impaired membrane trafficking) and the S156A
mutant (impaired phosphorylation at Ser 156 by PKA) do not induce cell migration and invasion in either BEAS-2B cells or NIH3T3 cells as compared
to Mock.
doi:10.1371/journal.pone.0002162.g002
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examine the molecular events leading to NSCLC development
[26]. In fact, we had previously reported that in BEAS-2B cells,
membranous expression of AQP5 is not necessarily associated
cAMP induced phosphorylation of AQP5 [17]. In this study, we
have used full length wild-type AQP5(AQP5) and its two mutants,
S156A and N185D, to examine the effect of PKA pathway
(S156A) and NPA motif related with membrane trafficking
(N185D), respectively, on cell invasion activity of BEAS-2B. We
did so based on our previous finding that in NIH3T3 mouse
fibroblast cells, while decreased cell proliferation in S156A mutant
was due to the poor activation of Ras/ERK pathway, in the case
of N185D mutant, it was owing to the improper trafficking of
AQP5 into the cell membrane [13]. In this study, AQP5 induced
cell invasion in BEAS-2B cells as well as NIH3T3 cells. In contrast,
both of the N185D and S156A mutants failed to induce any
significant cell invasion in either BEAS-2B cells or NIH3T3 cells
compared with mock. Overall, our result suggests that both
phosphorylation of AQP5 in PKA site (S156A) and membrane
targeting (N185D) are likely to be critical for the enhanced cell
invasion induced by AQP5.
Of note, we have found that the expression of AQP5 in BEAS-
2B cells promotes both cell invasion and proliferation. Interest-
ingly, even before we see the effects of cell proliferation, cells
become highly invasive (Fig. 2, Fig S1). This may explain, in part,
why some of the lung cancers are highly invasive in nature and
easily metastasize even when the size of tumor mass is small.
Additionally, the expression of AQP5 in BEAS-2B cells caused a
spindle-like and fibroblastic morphology and a loss of cell-to-cell
contacts and cell polarity. We have not found comparable changes
in cell morphology with mouse NIH3T3 cell line which is already
a fibroblast cell line and various other cancer cell lines including
colon cancer cell lines (HCT116, DLD1) and leukemic cell lines
(K562, LAMA-84). In our previous findings with AQP1 in lung
cancer [15], no notable morphologic changes in AQP1 transfected
cells were reported. We surmise that the transfection of AQP5 into
the normal epithelial cell line may have played a role in inducing
fibroblast-like morphologic alteration. However, further transfec-
tion of different types of AQPs into normal human bronchial
epithelial cell line is planned.
Expression assay of epithelial proteins such as E-cadherin, a-
catenin and c-catenin, and mesenchymal proteins including
fibronectin and vimentin in the BEAS-2B cells transfected with
AQP5 and its two mutants demonstrated that only cells with
AQP5, but none of the mutants, exhibited a loss of epithelial cell
markers and a gain of mesenchymal cell markers. Therefore, both
morphological modification and molecular profile change suggest
that AQP5 expression in BEAS-2B cells induces EMT, thus
promoting cell invasion and metastasis.
To elucidate the molecular interaction between AQP5 and its
downstream pathway leading to cell invasion with enhanced EMT
activity, we hypothesized that the diproline peptide sequence
(RTSPVGSP) in loop D of AQP5 is likely to be involved [18,19] in
its interaction with other adaptor proteins. Due to its sequence
similarity to SH3 binding consensus, it is possible that this
particular sequence can directly bind with the SH3 domain of
certain adaptor molecules [18,19]. Therefore, to identify candi-
date adaptor molecules which, directly or indirectly, bind to AQP5
through this particular amino acid sequences, we have screened a
human SH3 domains protein array. Interestingly, cellular extracts
from AQP5 showed a robust binding to SH3 domains of several
key proteins associated with signal transduction including c-Src,
Lyn, and Grap2 (Fig. 5A). Particularly, a phosphorylated Loop D
fragment of AQP5 (88 aa through 182 aa) was able to bind to the
Figure 3. The Morphologies of stable cells expressing AQP5
and mutants. The morphologies of the BEAS-2B human bronchial
epithelial cells expressing the mock vector FLAG or FLAG/AQP5 were
revealed by phase contrast microscopy. BEAS-2B cells maintained highly
organized cell-to-cell adhesion and cell polarity as a typical epithelial
morphology. The expression of AQP5 caused a spindle-like and
fibroblastic morphology and loss of cell-cell contacts and cell polarity.
Scale bars, 50 mm.
doi:10.1371/journal.pone.0002162.g003
Figure 4. Immunoblotting analysis of epithelial-mesenchymal
transition markers in stable cells expressing AQP5 and
mutants. Expression of epithelial proteins including E-cadherin, a-
catenin and c-catenin, and mesenchymal proteins including fibronectin
and vimentin was examined by immunoblotting in the four separate
BEAS-2B cells, each of which carries overexpression construct for AQP5
(clone #1 and #2), N185D, S156A and Mock. Only cells with AQP5
exhibited a loss of epithelial markers and a gain of mesenchymal cell
markers. 1, AQP5 clone#1; 2, AQP5 clone#2; 3, N185D; 4, S156A; 5,
Mock based on BEAS-2B cell lines.
doi:10.1371/journal.pone.0002162.g004
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AQP5, while unphosphorylated Loop D fragment was not
(Fig. 5A). Of note, our competitive inhibition assay using
phosphorylated and unphosphoryalated Loop D fragment showed
that only the phosphorylated Loop D fragment inhibited cell
proliferation in NIH3T3 cells (Lee et al., manuscript submitted),
further suggesting that phosphorylation of Loop D is likely to be
critical in the interaction of AQP5 with its adaptor molecules
involved in the signal transduction pathways of cell proliferation,
migration, and invasion such as c-Src [27]. These findings
altogether indicate that both the diproline peptide sequence in
Loop D and phosphorylation of Ser156 inside the diproline
peptide sequence by PKA are required to interact with Src family
molecules.
Src is a non-receptor cytoplasmic tyrosine kinase associated with
invasive and metastatic phenotype in various tumors and has been
known to promote EMT [27–29]. The role of c-Src has also been
emphasized in the carcinogenesis of NSCLC [30]. The activated,
or the phosphorylated form (Tyr416) of c-Src favors invasion by
disrupting E-cadherin dependent cell-to-cell contact and enhanc-
ing integrin mediated cell-matrix adhesion [31]. Our finding with
c-Src is important because AQP5 seems to interact only with the
activated form of c-Src (Fig. 5C). More interestingly, the cells with
AQP5 were shown to have more activated c-Src than the cells with
N185D or S156A mutant (Fig. 5C), hinting that the interaction
with AQP5 may induce a conformational change in the
inactivated c-Src, enabling it to become phosphorylated, and
thus, activated. Overall, our findings on the interaction of AQP5
with c-Src, based on several experiments: in vitro SH3 domain
protein array and GST pull-down assay and in vivo immunopre-
cipitation, offers a plausible explanation for the molecular
mechanism of AQP5 mediated enhanced invasion and EMT.
Finally, to determine the molecular mechanisms underlying the
expression of AQP5 in NSCLC, we performed FISH analysis. We
were unable to detect any clear evidence of genomic amplification,
which indicates that AQP5 expression is likely to be a secondary
event. Of note, this finding is similar to the case for AQP1, where
no evidence for genomic amplification was identified [15]. Further
efforts to identify promoter element responsible for the induced
expression of AQP5 in several tumor cell lines suggested several
potential cis-acting elements responsible for promoter activity. In
addition, methylation analysis of AQP5 promoter regions
suggested a possible role of promoter demethylation as a
mechanism of AQP5 expression in NSCLC (Kim et al.,
unpublished result). However, these results are still preliminary
and warrant further validation in the future.
We have previously reported that the phosphorylation of AQP5
at the PKA consensus site may play a role in promoting cell
transformation [13]. In a more recent study, phosphorylation of
AQP5 was reported in the tissues of human non small cell lung
cancer, but not in normal lung tissues [14]. While it is possible that
activation of AQP5 may lead to increase in its water permeability
and thus increase the metabolic capacity of the cell, it appears to
be unlikely, as data in Xenopus oocytes suggest otherwise [32].
Yang et al. reported that water channel (including AQP5)
phosphorylation by protein kinases A and C did not affect water
permeability [32]. Although, there still exists a possibility that
AQP5 mediated water transport may, in part, play a role in cell
migration as in AQP4 [33], the role of water transport may not be
significant compared with the suggested c-Src mediated epithelial
mesenchymal transition (EMT) promoting property of AQP5.
In summary, our clinical and molecular findings support our
hypothesis that AQP5 may play a critical role in the progression of
NSCLC through enhanced cell invasion. This contrasts to other
reports showing the role of AQPs in cell proliferation (AQP1 and
AQP5) or angiogenesis (AQP1) [11,13–15]. It, further, makes
hAQP5 an attractive molecular marker for predicting cancer
prognosis. Moreover, a significant expression level of AQP5
(35.3%, 144/408) in NSCLC and its association with worse
clinical outcomes may warrant a future study to explore AQP5 as
a novel therapeutic target for the management of NSCLC. For
example, one of the standard second line therapies of lung
adenocarcinoma in the U.S. is the use of epidermal growth factor
(EGFR) antagonist, erlotinib, which inhibits tyrosine kinase
activity of EGFR [34]. We surmise that in the future, AQP5
antagonists, possibly through inhibition of phosphorylation in
S156 or its interaction with downstream pathways, may be used
for the management of NSCLC.
Supporting Information
Figure S1 Cell proliferation assay between BEAS 2B cells
transfected AQP5 and mock. (left) Immunoblotting was done to
confirm the overexpression of AQP5 in human bronchial
epithelial cells stably transfected with AQP5. Mock transfected
cells showed no expression of AQP5. Actin was loaded as control.
(right) Cell proliferation was measured with MTT assay 1 day and
Figure 5. Interaction between AQP5 and the Src family
molecules. (A) A human SH3 domains protein array was used to
examine the potential binding activities of several SH3 domain-
containing proteins to AQP5. Not only AQP5, but also AQP5 segment
containing a phosphorylated Loop D (88 aa through 182 aa) were
found to bind to the SH3 domain of the c-Src, the Lyn, and the Grap2
protein. The AQP5 segment containing an unphosphorylated Loop D,
however, was unable to bind to the SH3 domain of any of these
proteins. (B) GST pull-down assay was performed with three different
GST fusion proteins: a c-Src SH3 domain, a Lyn SH3 domain, and a C-
terminal Grap2 SH3 domain protein. Cells stably expressing AQP5 in
human bronchial epithelial cells, BEAS-2B, revealed a strong interaction
with the c-Src SH3 domain protein, the Lyn SH3 domain protein and the
C-terminal Grap2 SH3 domain protein. (C) AQP5 is co-immunoprecip-
itated with c-Src in the BEAS-2B cells stably transfected with AQP5
expression construct. Furthermore, only an activated form of c-Src,
phosphorylated on Tyr 416, is co-immunoprecipitated with AQP5. 1,
Mock; 2, N185D; 3, S156A; 4, AQP5; M, molecular weight marker.
doi:10.1371/journal.pone.0002162.g005
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PLoS ONE | www.plosone.org 8 May 2008 | Volume 3 | Issue 5 | e21622 days after seeding at a density of 16104 cells/well in six-well
plates (triplets). After 2 days, cells transfected demonstrated
significantly higher proliferation rate than cells transfected with
mock (p,0.01).
Found at: doi:10.1371/journal.pone.0002162.s001 (0.09 MB
DOC)
Figure S2 FISH analysis of AQP5. In the FISH analysis, no
genomic amplification is identified in any of 60 NSCLCs tested,
and one representative example is shown. (green color: FITC
labeled control probe, red color: rhodamin labeled AQP5 probe).
Original magnification 61000 (f).
Found at: doi:10.1371/journal.pone.0002162.s002 (0.08 MB
DOC)
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